These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 12077264)

  • 21. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
    Bermúdez-Humarán LG; Cortes-Perez NG; Lefèvre F; Guimarães V; Rabot S; Alcocer-Gonzalez JM; Gratadoux JJ; Rodriguez-Padilla C; Tamez-Guerra RS; Corthier G; Gruss A; Langella P
    J Immunol; 2005 Dec; 175(11):7297-302. PubMed ID: 16301635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor.
    Ossevoort MA; Feltkamp MC; van Veen KJ; Melief CJ; Kast WM
    J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):86-94. PubMed ID: 8574470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
    Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
    Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
    De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
    Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects.
    Indrová M; Reinis M; Bubeník J; Jandlová T; Bieblová J; Vonka V; Velek J
    Folia Biol (Praha); 2004; 50(6):184-93. PubMed ID: 15709713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
    Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
    J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells.
    Chen XZ; Mao XH; Zhu KJ; Jin N; Ye J; Cen JP; Zhou Q; Cheng H
    Arch Dermatol Res; 2010 Jan; 302(1):57-65. PubMed ID: 19578865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses.
    Kim D; Monie A; He L; Tsai YC; Hung CF; Wu TC
    Gene Ther; 2008 May; 15(9):677-87. PubMed ID: 18273057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization against human papillomavirus infection and associated neoplasia.
    Osen W; Jochmus I; Müller M; Gissmann L
    J Clin Virol; 2000 Oct; 19(1-2):75-8. PubMed ID: 11091150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
    Peng S; Frazer IH; Fernando GJ; Zhou J
    Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein.
    Liu H; Wu BH; Rowse GJ; Emtage PC
    Clin Vaccine Immunol; 2007 Aug; 14(8):1013-23. PubMed ID: 17596433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
    Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
    J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
    J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice.
    Wang X; Che Y; Chen B; Zhang Y; Nakagawa M; Wang X
    Int Immunopharmacol; 2018 Mar; 56():249-260. PubMed ID: 29414659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
    Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
    J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies.
    Kim TW; Hung CF; Boyd D; Juang J; He L; Kim JW; Hardwick JM; Wu TC
    J Immunol; 2003 Sep; 171(6):2970-6. PubMed ID: 12960321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.